Checkpoint Capital L.P. Axsome Therapeutics, Inc. Transaction History
Checkpoint Capital L.P.
- $202 Billion
- Q3 2024
A detailed history of Checkpoint Capital L.P. transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Checkpoint Capital L.P. holds 209,632 shares of AXSM stock, worth $18.8 Million. This represents 9.35% of its overall portfolio holdings.
Number of Shares
209,632
Previous 290,772
27.91%
Holding current value
$18.8 Million
Previous $23.4 Billion
19.51%
% of portfolio
9.35%
Previous 14.11%
Shares
4 transactions
Others Institutions Holding AXSM
# of Institutions
326Shares Held
37.7MCall Options Held
912KPut Options Held
855K-
Rtw Investments, LP New York, NY4.19MShares$376 Million6.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4MShares$358 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$296 Million0.01% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA2.36MShares$212 Million34.46% of portfolio
-
Bvf Inc San Francisco, CA1.05MShares$93.8 Million2.99% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $3.85B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...